Core Viewpoint - Apimeds Pharmaceuticals US, Inc. has announced the pricing of its initial public offering (IPO) of 3,375,000 shares at $4.00 per share, aiming to raise approximately $13.5 million in gross proceeds [1][2]. Group 1: IPO Details - The IPO is expected to close on May 12, 2025, and shares will begin trading on the NYSE American under the symbol "APUS" on May 9, 2025 [2]. - The underwriters have a 45-day option to purchase an additional 506,250 shares at the public offering price, and they have been issued warrants for up to 168,750 shares [2]. Group 2: Use of Proceeds - The net proceeds from the IPO will be utilized to fund a Phase III clinical trial for knee osteoarthritis, initiate a corporate sponsorship study in multiple sclerosis, manufacture the product candidate, and cover general working capital needs [3]. Group 3: Company Overview - Apimeds is a clinical stage biopharmaceutical company developing Apitox, a bee venom-based toxin administered intradermally, which is being targeted as a treatment for osteoarthritis in patients who do not respond to conventional therapies [6].
Apimeds Pharmaceuticals US, Inc. Announces Pricing of Initial Public Offering
Globenewswireยท2025-05-08 21:00